MLN8237 and Pazopanib in Combination for Solid Tumors
This trial is active, not recruiting.
|Conditions||malignant neoplasm of breast, cns malignancy, malignant neoplasm of gastrointestinal tract, genitourinary neoplasms malignancy and gender unspecified, head and neck neoplasms, melanoma, malignant neoplasm of thorax|
|Targets||VEGF, PDGF, ARK-1, KIT|
|Sponsor||University of Illinois at Chicago|
|Collaborator||Millennium Pharmaceuticals, Inc.|
|Start date||August 2013|
|End date||March 2017|
|Trial size||30 participants|
|Trial identifier||NCT01639911, 2011LS054, X14011|
This phase I dose escalation study will evaluate alisertib, an Aurora A kinase inhibitor, when given in combination with the selective vascular endothelial growth factor receptor (VEGFR) inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.
|Endpoint classification||safety study|
|Intervention model||single group assignment|
Optimally Tolerated Dose
time frame: At end of Cycle 1 (approximately Day 21)
time frame: Within 30 days of Last Treatment Dose
Male or female participants at least 18 years old.
- Diagnosis of advanced non-hematologic solid tumor malignancy that has failed/become intolerant to standard therapy
- Measurable disease per RECIST
- Age ≥ 18 years
- ECOG PS of 0-2
- Prior systemic chemotherapy, immunotherapy, or biological therapy is allowed; however prior use of study drugs in combination is not allowed.
- Must have recovered from the reversible effects of previous anti-cancer tx
- Adequate organ function within 14 days of study registration
- Patient must be able to take oral medication and to maintain a fast as required for 2 hrs before and 2 hrs after alisertib admin.
- Subjects agrees to use contraception, as needed
- Untreated or symptomatic CNS metastases
- Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is excluded.
- Prior allogeneic BMT
- >or = Grade 2 peripheral neuropathy within 14 days before enrollment
- Known history of uncontrolled sleep apnea & other conditions that could result in excessive daytime sleepiness
- Requirement for constant admin. of proton pump inhibitor, H2 antagonist, or pancreatic enzymes.
- Systemic infection requiring IV antibiotics within 14 days preceding the 1st dose of study drug, or other severe infection.
- MI within 6 mos. prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, CVA, pulmonary embolism or untreated DVT or evidence of acute ischemia or active conduction system abnormalities on ECG (e.g., repeated QTc interval > 450 msec)
- Pregnant or breast-feeding.
- Patient has received other investigational drugs with 14 days
- Serious medical/psychiatric illness in the opinion of the PI would likely interfere with participation
- Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- Treatment with clinically significant enzyme inducers, such as the enzyme inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days
- Known history of HIV infection, hepatitis B, or hepatitis C.
- Recent (within 6 months) arterial thromboembolic events, including TIA, CVA, unstable angina, or MI. Pts. with clinically significant PAD are ineligible.
- History of thrombotic or hemorrhagic disorders, not receiving chronic daily treatment with ASA (>325 mg/day) or NSAIDs known to inhibit platelet function. Treatment with dipyridamole (persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and/or cilostazol (Pletal).
- History of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
- Clinically significant GI abnormalities that may affect absorption of IP including, but not limited to:
- Ongoing nausea or vomiting of any severity
- > grade 1 diarrhea
- Malabsorption syndrome
- Major resection of stomach or small bowel
- Inability to swallow oral medications or inability to take nothing by mouth except water and prescribed medications for 2 hrs before and 2 hrs after each dose of alisertib.
- Poorly controlled HTN [SBP of ≥140 mmHg or DBP of ≥ 90mmHg].
- Prior major surgery/trauma within 28 days or presence of any non-healing wound, fracture, or ulcer
- Evidence of active bleeding
- Known endobronchial lesions or involvement of large pulmonary vessels by tumor or centrally located pulmonary cavitating lesion
- Hemoptysis within 6 weeks
- Unable or unwilling to D/C use of prohibited medications for at least 14 days prior to the 1st dose of study drug and for the duration of the study
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to pazopanib or alisertib
|Official title||Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors|
|Principal investigator||Arkadiusz Z. Dudek, M.D.|
|Description||Alisertib is taken orally twice a day for the 1st 7 days of a 21 day cycle. Pazopanib is taken orally once a day continuously beginning on day 10 of cycle 1 to allow for alisertib pharmacokinetics (PKs). Treatment continues until disease progression, unacceptable toxicity, or patient refusal. PKs will be done on all patients in association with the last dose of alisertib cycles 1 and 2.|
Call for more information